Indicadores de Prod. Científica
Publicaciones Científicas
Patentes
Gaceta Electrónica de I+D
Ayuda
Descripción de Contenidos
Uso de la Página
Sugerencias y Propuestas
Convocatorias y
Documentos
Convocatorias y Ayudas de I+D
Documentos e Informes
Normativa
Recursos Investigación
Centros de Investigación
Grupos de Investigación
Investigadores
Equipamientos de I+D
Comités Eticos
Actividad Investigadora
Proyectos de Investigación
Ensayos Clínicos
Indicadores
Nuevos Proyectos
Resultados Investigación
Indicadores Prod. Científica
Publicaciones Científicas
Patentes
Gaceta Electrónica de I+D
Formación
Apoyo Metodológico
Oferta Formativa
Bibliografía Seleccionada
Recursos Metodológicos
Recursos Bibliográficos
Otros Recursos
Museo de la Sanidad
Enlaces de Interés
Ofertas de Trabajo
y Colaboración
Noticias
Eventos
ADAPTATION OF THE CHEMOTHERAPY PRESCRIPTION FOR BREAST CANCER IN A TERTIARY HOSPITAL. IMPACT ON SURVIVAL

Titulo

ADAPTATION OF THE CHEMOTHERAPY PRESCRIPTION FOR BREAST CANCER IN A TERTIARY HOSPITAL. IMPACT ON SURVIVAL 

Revista

ATEN FARM 

Año

2013 

Volumen

15 

Página Inicial

178 

Página Final

184 

Autores

Maria, APA; Ruth, UP; Angel, CHM; Patricia, AA; Barbara, CD; Monica, FM

Centros Participantes

[Ana Maria, Alanon Pardo; Miguel Angel, Calleja Hernandez; Diez Barbara, Candela; Martin Monica, Ferrit] Hosp Univ Virgen de las Nieves, Hosp Pharm, Pharm Serv, Granada, Spain; [Perez Ruth, Ubago] AETSA, Hosp Pharm, Seville, Spain; [Arroyo Patricia, Araque] Hosp La Mancha, Ctr Alcazar de San Juan, Pharm Serv, Hosp Pharm, Ciudad Real, Spain

Resumen

Objective: To analyze the degree of adaptation in the chemotherapy prescriptions for breast cancer therapy to the Integrated Care Process (ICP) and the Spanish Society of Gynecology and Obstetrics (SEGO) protocols; identify the causes of no-adaptation; and assess the survival rate according to the adaptation. Method: A retrospective observational study was conducted on patients who were diagnosed with breast cancer in 2006 and treated with chemotherapy since that year. A follow-up was performed until December 2010. Results: 131 patients who received a total of 189 treatments were included. The overall adaptation to the ICP was 27% and 21.7% to the SEGO. The most frequent causes of no adaptation were related to the indication and the used regimen. The five year survival rate in the groups of no-adaptation to both protocols was higher than the calculated for the groups of yes-adaptation, with statistically significant differences in both cases. Conclusions: The degree of adaptation to both protocols is low and does not seem to be directly related to an improvement in the survival rate.
Datos adjuntos
Tipo de contenido: PublicacionesCientificas
Creado el 11/05/2017 13:41  por Cuenta del sistema 
Última modificación realizada el 11/05/2017 13:41  por Cuenta del sistema